Patents by Inventor William H. Robinson
William H. Robinson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20150079083Abstract: The invention provides methods for treating inflammatory diseases by administering to the subject an effective amount of an agent that provides alpha B-crystallin activity, where the dose is effective to suppress or prevent initiation, progression, or relapses of disease, including the progression of established disease. In some embodiments, the methods of the invention comprise administering to a subject having a pre-existing inflammatory disease condition, an effective amount of alpha B-crystallin protein, to suppress or prevent relapses of the disease.Type: ApplicationFiled: July 7, 2014Publication date: March 19, 2015Inventors: Lawrence Steinman, Shalina Sheryl Ousman, William H. Robinson
-
Publication number: 20140275164Abstract: Compositions and methods are provided for inhibiting or treating the early and established stages of inflammatory diseases by administration of an effective dose of the desethylhydroxychloroquine (DHCQ). A benefit of the methods is the ability to deliver a dose of agent that is effective in treating inflammation while sparing the individual from retinal toxicity.Type: ApplicationFiled: March 14, 2014Publication date: September 18, 2014Inventors: William H. Robinson, Jeremy Sokolove, Qian Wang
-
Patent number: 8835391Abstract: The invention provides methods for treating inflammatory diseases by administering to the subject an effective amount of an agent that provides alpha B-crystallin activity, where the dose is effective to suppress or prevent initiation, progression, or relapses of disease, including the progression of established disease. In some embodiments, the methods of the invention comprise administering to a subject having a pre-existing inflammatory disease condition, an effective amount of alpha B-crystallin protein, to suppress or prevent relapses of the disease.Type: GrantFiled: January 21, 2011Date of Patent: September 16, 2014Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Lawrence Steinman, Shalina Sheryl Ousman, William H. Robinson
-
Patent number: 8771689Abstract: The invention provides methods for treating inflammatory diseases by administering to the subject an effective amount of an agent that provides alpha B-crystallin activity, where the dose is effective to suppress or prevent initiation, progression, or relapses of disease, including the progression of established disease. In some embodiments, the methods of the invention comprise administering to a subject having a pre-existing inflammatory disease condition, an effective amount of alpha B-crystallin protein, to suppress or prevent relapses of the disease.Type: GrantFiled: June 23, 2011Date of Patent: July 8, 2014Assignees: The Board of Trustees of the Leland Stanford Junior University, Department of Veterans AffairsInventors: Lawrence Steinman, Shalina Sheryl Ousman, William H. Robinson
-
Publication number: 20140066469Abstract: Compositions and methods are provided for preventing or treating the pre-clinical early-stages of inflammatory diseases, including autoimmune diseases, degenerative inflammatory diseases, metabolic inflammatory diseases, chronic infection associated with inflammation, cancer associated with inflammation, and other inflammatory diseases by administration to an individual of an effective dose of a synergistic combination of active agents comprising or consisting essentially of an aminoquinoline, e.g. hydroxychloroquine, and a statin, e.g. atorvastatin. Each or both of the active agents can be formulated in various ways, including without limitation a solid oral dosage form.Type: ApplicationFiled: August 21, 2013Publication date: March 6, 2014Inventors: William H. Robinson, Jeremy Sokolove, Qian Wang, Heidi H. Wong, Mark C. Genovese
-
Publication number: 20140011755Abstract: The invention provides methods for treating inflammatory and autoimmune diseases by administering to the subject an effective amount of a cardiac glycoside, where the dose is effective to suppress or prevent initiation, progression, or relapses of the disease, including the progression of established disease. In some embodiments, the methods of the invention comprise administering to a subject determined to have rheumatoid arthritis or systemic lupus, or a pre-clinical disease state thereof, an effective amount of a cardiac glycoside, to suppress or prevent activity of the disease. In other embodiments, the methods of the invention comprise administering to a subject determined to have insufficient endogenous cardiac glycosides, an effective amount as a supplement to counteract the effects of cardiac glycoside deficiency.Type: ApplicationFiled: December 13, 2011Publication date: January 9, 2014Applicants: Department of Veterans Affairs, The Board of Trustees of the Leland Stanford Junior UniversityInventors: Emily A. Stein, William H. Robinson, Ricardo T. Paniagua
-
Publication number: 20130052186Abstract: Compositions and methods are provided for prognostic classification of individuals into groups that are informative of the individual's likelihood of developing severe disease associated with undesirable complement activation. Individuals having one or both alleles for a more stable or active carboxypeptidase B variant have a reduced propensity for developing severe disease. The presence of the protective variant may be identified through any suitable method.Type: ApplicationFiled: June 8, 2012Publication date: February 28, 2013Inventors: Jungsik Song, William H. Robinson
-
Patent number: 8252775Abstract: To perform large-scale multiplex analysis of lipid-specific binding, lipid microarrays were developed. Lipids identified as disease associated, or analogs there, can be tolerogenic to patients suffering from autoimmune disease. Lipid array analysis has revealed anti-lipid antibodies in patients with immune disorders, and may contribute to the pathogenesis of disease.Type: GrantFiled: July 21, 2006Date of Patent: August 28, 2012Assignees: The Board of Trustees of the Leland Stanford Junior University, U.S. Department of Veteran AffairsInventors: Jennifer L. Kanter, William H. Robinson, Lawrence Steinman
-
Patent number: 8148084Abstract: Methods and compositions for diagnosing and treating autoimmune disease, e.g., acute disseminated encephalomyelitis (ADEM), are described.Type: GrantFiled: June 21, 2007Date of Patent: April 3, 2012Assignees: Dana-Farber Cancer Institute, Inc., Brigham and Women's Hospital, Inc., The Trustees of the Leland Stanford Junior University, Department of Veterans AffairsInventors: Kevin C. O'Connor, David A. Hafler, Kai W. Wucherpfennig, Katherine McLaughlin, William H. Robinson, Lawrence Steinman
-
Publication number: 20110318346Abstract: The invention provides methods for treating inflammatory diseases by administering to the subject an effective amount of an agent that provides alpha B-crystallin activity, where the dose is effective to suppress or prevent initiation, progression, or relapses of disease, including the progression of established disease. In some embodiments, the methods of the invention comprise administering to a subject having a pre-existing inflammatory disease condition, an effective amount of alpha B-crystallin protein, to suppress or prevent relapses of the disease.Type: ApplicationFiled: June 23, 2011Publication date: December 29, 2011Inventors: Lawrence Steinman, Shalina Sheryl Ousman, William H. Robinson
-
Publication number: 20110160142Abstract: The invention provides methods for treating inflammatory diseases by administering to the subject an effective amount of an agent that provides alpha B-crystallin activity, where the dose is effective to suppress or prevent initiation, progression, or relapses of disease, including the progression of established disease. In some embodiments, the methods of the invention comprise administering to a subject having a pre-existing inflammatory disease condition, an effective amount of alpha B-crystallin protein, to suppress or prevent relapses of the disease.Type: ApplicationFiled: January 21, 2011Publication date: June 30, 2011Inventors: Lawrence Steinman, Shalina Sheryl Ousman, William H. Robinson
-
Publication number: 20110047632Abstract: Compositions and methods are provided for prognostic classification of rheumatoid arthritis disease patients into subtypes, which subtypes are informative of the patient's need for therapy and responsiveness to a therapy of interest.Type: ApplicationFiled: August 4, 2010Publication date: February 24, 2011Inventors: William H. Robinson, Peggy Pui-Kay Ho, Xiaoyan Zhao, Lawrence M. Steinman
-
Patent number: 7875589Abstract: The invention provides methods for treating inflammatory diseases by administering to the subject an effective amount of an agent that provides alpha B-crystallin activity, where the dose is effective to suppress or prevent initiation, progression, or relapses of disease, including the progression of established disease. In some embodiments, the methods of the invention comprise administering to a subject having a pre-existing inflammatory disease condition, an effective amount of alpha B-crystallin protein, to suppress or prevent relapses of the disease.Type: GrantFiled: December 11, 2007Date of Patent: January 25, 2011Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Lawrence Steinman, Shalina Sheryl Ousman, William H. Robinson
-
Publication number: 20100330110Abstract: This invention provides a method for determining the antibody specificity profile in an individual. This specificity profile reveals the individual's immune response to multiple antigens and/or epitopes of autoantigens, allergens, graft antigens, etc. The antibody specificity profile is determined through the binding of patient samples comprising antibodies to the arrays. The array can comprises antigens and epitopes. The invention also provides the means and methods for determining antigen or epitope specificity profiles that can be used in the development of either generic and individualized diagnosis and treatment for immune related diseases, including autoimmune disease, allergy and graft rejection.Type: ApplicationFiled: August 30, 2010Publication date: December 30, 2010Applicant: The Board of Trustees of the Leland Stanford Junior UniversityInventors: William H. Robinson, David L. Hirschberg, Lawrence Steinman, Pedro Jose Ruiz, Paul J. Utz, Hideki Garren
-
Patent number: 7785819Abstract: This invention provides a method for determining the antibody specificity profile in an individual. This specificity profile reveals the individual's immune response to multiple antigens and/or epitopes of autoantigens, allergens, graft antigens, etc. The antibody specificity profile is determined through the binding of patient samples comprising antibodies to the arrays. The array can comprises antigens and epitopes. The invention also provides the means and methods for determining antigen or epitope specificity profiles that can be used in the development of either generic and individualized diagnosis and treatment for immune related diseases, including autoimmune disease, allergy and graft rejection.Type: GrantFiled: April 10, 2002Date of Patent: August 31, 2010Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: William H. Robinson, David L. Hirschberg, Lawrence Steinman, Pedro Jose Ruiz, Paul J. Utz, Hideki Garren
-
Publication number: 20100204058Abstract: The present invention relates to compositions and methods for treating, characterizing, and diagnosing autoimmune diseases or other inflammatory diseases. In particular, the present invention provides gene expression profiles as well as novel TKI Responsive Signature(s) useful for the diagnosis, characterization, prognosis and treatment of autoimmune disease or other inflammatory diseases.Type: ApplicationFiled: January 27, 2010Publication date: August 12, 2010Inventors: Howard Yuan-Hao Chang, William H. Robinson, David Fiorentino, Lorinda Chung, Adam Adler
-
Patent number: 7739829Abstract: Insect pests can be transported around the world in wooden shipping containers. To prevent the spread of wood-borne insect pests, it is necessary to kill insects within the wood. The wood is placed in a vacuum container having a flexible wall. The flexible wall presses against the wood and enables the wood to be heated by conduction. The wood and flexible wall can to be heated by contact with ambient or heated air, for example. Desiccant or dry air can be used to increase the rate of dehydration. Insects in the wood are typically killed after losing 25-50% of their body weight by dehydration. This technique will kill beetle larvae, nematodes and other invasive and destructive insects that live inside solid wood, and is particularly applicable for rendering wood acceptable for use in pallets and other containers shipped internationally.Type: GrantFiled: July 11, 2005Date of Patent: June 22, 2010Assignee: Virginia Tech Intellectual Properties, Inc.Inventors: Zhangjing Chen, Marshall S. White, William H. Robinson
-
Publication number: 20090324585Abstract: The present disclosure is directed to methods and compositions for treating osteoarthritis and preventing osteoarthritis, by administering a compound that modulates one or more components in the complement system. In one embodiment, a compound that inhibits a component in the complement system is administered to prevent, delay the progression of, or treat osteoarthritis. In other embodiments, compounds with specific inhibition of a component in a particular pathway in the complement system, such as the alternative, mannose binding lectin, and/or classical pathway, are administered to a subject having osteoarthritis or at risk of developing osteoarthritis.Type: ApplicationFiled: June 11, 2009Publication date: December 31, 2009Applicant: The Trustees of the Leland Standford Junior UniversityInventors: William H. Robinson, V. Michael Holers, Andrew L. Rozelle
-
Publication number: 20090281170Abstract: This invention provides a method of treating or preventing a disease in an animal associated with one or more self-protein(s), -polypeptide(s), or -peptide(s) that is present or involved in a non-physiologic process in the animal comprising administering to the animal a self-vector comprising a polynucleotide encoding the self-protein(s), -polypeptide(s) or -peptide(s) associated with the disease. Administration of the self-vector comprising a polynucleotide encoding the self-protein(s), -polypeptide(s) or -peptide(s) modulates an immune response to the self-protein(s), -polypeptide(s) or -peptide(s) expressed from administration of the self-vector.Type: ApplicationFiled: May 18, 2009Publication date: November 12, 2009Applicants: The Board of Trustees of the Leland Stanford Junior University, Bayhill Therapeutics/StanfordInventors: Paulo Fontoura, Hideki Garren, William H. Robinson, Lawrence Steinman, Pedro Jose Ruiz, Paul J. Utz
-
Publication number: 20090264515Abstract: This invention provides a method of treating or preventing a disease in an animal associated with one or more self-protein(s), -polypeptide(s), or -peptide(s) that is present or involved in a non-physiologic process in the animal comprising administering to the animal a self-vector comprising a polynucleotide encoding the self-protein(s), -polypeptide(s) or -peptide(s) associated with the disease. Administration of the self-vector comprising a polynucleotide encoding the self-protein(s), -polypeptide(s) or -peptide(s) modulates an immune response to the self-protein(s), -polypeptide(s) or -peptide(s) expressed from administration of the self-vector.Type: ApplicationFiled: May 18, 2009Publication date: October 22, 2009Applicants: The Board of Trustees of the Leland Stanford Junior University, Bayhill Therapeutics/StanfordInventors: Paulo Fontoura, Hideki Garren, William H. Robinson, Lawrence Steinman, Pedro Jose Ruiz, Paul J. Utz